Our experience of using hexane extract of Serenoa Repens fruit (Permixone) in the treatment of LUTS in clinical practice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are among the most common causes of LUTS in men. LUTS occur on average in 62.5% of males, with irritative symptoms occurring in 51%, obstructive symptoms in 26%, and postmicturic symptoms in 17% of cases. According to the literature, moderate and severe LUTS were observed in 13% of men under the age of 50 and in 28% after 70 years. It should be noted that LUTS are not BPH-specific, since may be caused by prostate inflammation. According to publications, 57% of patients examined for CP have BPH, and 39% of patients with BPH have CP. The first line of drug therapy in patients with BPH is currently considered to be alpha-blockers and inhibitors of 5-α-reductase. In addition, it is possible to use herbal preparations made from fruits, roots, seeds, pollen and plant bark. Preparations based on Serenoa repens extract are among the most studied and are widely used both in our country and worldwide for the treatment of patients with BPH and LUTS. Only lipidosterol hexane extract of Serenoa repens is recognized as a drug, the use of which has a good evidence base. The clinical examples illustrating the pharmacological properties and results of the use of the preparation of lipidosterol hexane extract Serenoa repens are presented in the article. Conclusion. The presented clinical cases demonstrate the efficiency of the hexane extract of Serenoa repens fruit for the treatment of LUTS associated with BPH and CP. At the same time, the drug can be effectively used both as monotherapy and in combination with alpha-blockers. Therefore, it is reasonable to use the hexane extract of Serenoa repens fruit in clinical practice for the treatment of LUTS associated with BPH.

Full Text

Restricted Access

About the authors

A. V Kuzmenko

Voronezh State Medical University named after N.N. Burdenko

Email: kuzmenkoav09@yandex.ru
Ph.D., MD, professor, professor at the Department of Specialized Surgical disciplines

T. A Gyaurgiev

Voronezh State Medical University named after N.N. Burdenko

Email: tima001100@mail.ru
Ph.D., associate professor at the Department of Specialized Surgical disciplines

G. A Kuzmenko

Voronezh State Medical University named after N.N. Burdenko

Email: tima001100@mail.ru
first-year student

References

  1. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018:480
  2. Gravas S., Cornu J.N., Gacci M, Gratzke C, Herrmann T.R.W., Mamoulakis C, Rieken M, Speakman M.J., TikkinenK.A.O. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), Incl. Benign Prostatic Obstruction (BPO); EAU Guidelines Office: Arnhem, The Netherlands, 2019. Available online: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/(accessed on 19 June 2020).
  3. Fitzpatrick J.M. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97:3-6.
  4. Berry S.J., Coffey D.S., Walsh P.C., Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3):474-479.
  5. Schaeffer A.J. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis/ Urology. 2002;60(6 Suppl):5-6; discussion 6-7. doi: 10.1016/s0090-4295(02)02292-6.
  6. Rees J., Abrahams M, Doble A., Cooper A. and the Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116:509-525. 10.1111/bju.13101' target='_blank'>https://doi: 10.1111/bju.13101
  7. Аль-Шукри С.Х., Амдий Р.Э. Диагностика инфравезикальной обструкции у больных аденомой предстательной железы. Урология. 2006;2:41-45
  8. Гаджиева З.К., Казилов Ю.Б. Новые возможности лечения комбинированных симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы - предпосылки и преимущества. Урология. 2017;1:95-102
  9. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Комбинированная медикаментозная терапия больных ДГПЖ. Урология. 2018;1:101-105
  10. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных с хроническим простатитом на фоне аденомы простаты. Системный анализ и управление в биомедицинских системах. 2017;16(3):513-516
  11. Taoka R, Kakehi Y. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J Urol 2017;4(3):158-163.
  12. Kudryavtsev Yu.V., Sivkov A.V. Morphological changes in prostate tissue in benign hyperplasia. Experimental and clinical urology. 2010;1:18-22.
  13. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Энтомологический препарат аденопросин в лечении пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2021;1:39-44
  14. European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus. (Electronic resource). http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-Herbal_monograph/2016/01/WC500199750.pdf (access date: 12.11.2019)
  15. Cornu J.N., Cussenot O., Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol. 2010;58:450-456
  16. Tacklind J., MacDonald R, Rutks I. et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012: CD001423. (Electronic resource). http://dx.doi.org/10.1002/14651858.CD001423.pub3 (access date: 12.11.2019)
  17. Laekeman G, Vlietinck A. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. (Electronic resource). URL: www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/ WC500179593.pdf (access date: 12.11.2019)
  18. Habib F.K., Wyllie M.G. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis. 2004;7:195-200.
  19. Latil A., Pe'trissans M.T., Rouquet J. et al. Effects of hexanic extract of Serenoa repens (Permixon1 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867.
  20. Scaglione F., Lucini V., Pannacci M. et al.Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur Rev Med Pharmacol Sci. 2012;16:569-574.
  21. Boyle P., Robertson C, Lowe F., Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004;93:751-756.
  22. Novara G, Giannarini G., Alcaraz A. et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus. 2016;2(5):553-561.
  23. Vela-Navarrete R., Alcaraz A., Rodriguez-Antolin A. et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/ BPH): systematic review and meta-analysis of randomized controlled trials and observational studies. BJU Int. 2018;122(6):1049-1065.
  24. Gravas S., Samarinas М., Zacharouli К. et al. The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol. 2019;37(3):539-544.
  25. Chevalier G., Benard P., Cousse H., Bengone T. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1-14C] -lauric acid, [1-14C] -oleic acid or [4-14C] -beta sitosterol. Eur J Drug Metab Pharmacokinet. 1997;22(1):73-83.
  26. Alcaraz A, Rodriguez J.C., Unda-Urzaiz M., Medina-Lopez R., Ruiz-Cerda J.L., Rodriguez-Rubio F., Garci'a-Rojo D., Brenes-Bermudez F.J., Cozar-Olmo J.M., Baena-Gonzalez V. et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: Change over time in real-life practice according to treatment-the QUALIPROST study.Int. Urol. Nephrol. 2016, 48, 645-656.
  27. Debruyne F., Koch G., Boyle P. et al.Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41:497-506.
  28. Glemain P., Coulange C., Billebaud T. et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial. Prog Urol. 2002;12:395-403.
  29. De la Taille A., et al. Alpha-bloquants ou phytotherapie en traitement de premiere intention des SBAU/HBP en medecine generale: l’etude non interventionnelle PERSAT. Prog Urol (2020), https://doi.org/10.1016/j.purol.2020.07.001
  30. Falahatkar S., Mokhtari G., Pourreza F. et al. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology. 2008;72(4): 813-816.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies